The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
Completion of the demerger of Haleon and share consolidation of GSK
The appointments will add to the well-diversified experience that currently exists on the PPL board.
The proposed combination involves corporate restructuring of JVCO, including through acquisition by Haleon via demerger
Steinberg brings nearly three decades of experience in biopharmaceutical equity research to Prolacta's executive team.
The proposed demerger is the most significant corporate change for GSK in the last 20 years
Besides enhancing workflow operations by connecting scientists with their lab instruments and data, digitalization holds the potential to acceleratee long-term business growth
He will be leading the business, operations, P&L, and growth strategy for StanPlus
Bringing together Bristol Myers Squibb and Celgene on one clinical trial management system, company goes live with Vault CTMS in record speed
Subscribe To Our Newsletter & Stay Updated
